Abstract: The present invention relates to a composition for diagnosing lung cancer including a preparation capable of measuring expression levels of lung cancer-specific biomarkers SAA, OPN, and CEA at the same time, a kit for diagnosing lung cancer including the same, and a method of diagnosing lung cancer using the composition. The composition for diagnosing lung cancer has effects such as enhanced sensitivity and specificity as compared to conventional biomarkers, thereby exhibiting high diagnostic efficiency.

Abstract: Provided are a composition for diagnosing breast cancer and a method of diagnosing breast cancer using the same. Breast cancer may be diagnosed using blood in a simple manner.

Abstract: A method of diagnosing small cell lung cancer comprises: measuring an expression level of serum paraoxonase 1 protein and a fucosylation level of the serum paraoxonase 1 protein in a biological sample from a small cell lung cancer patient and in a same biological sample from a normal person, and determining the expression level of the serum paraoxonase 1 protein is decreased in the biological sample of the small cell lung cancer patient as compared to the biological sample of a normal person, and the fucosylation level of the serum paraoxonase 1 protein is increased in the biological sample of the small cell lung cancer patient as compared to the biological sample of a normal person. The measuring of the fucosylation of the serum paraoxonase 1 protein comprises using a biotinylated lectin which binds specifically to fucose on the serum paraoxonase 1 protein and HRP-conjugated streptavidin in a hybrid ELISA.

Abstract: Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including Quescin-sulfhydryl oxidase 1, Fibrillin-1, Isoform A of Lamin-A/C, Latent-transforming growth factor beta-binding protein 2, Galectin-1, highly similar to Dickkopf-related protein 3, Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1, 14-3-3 protein epsilon, Stanniocalcin-2, Cystatin-C, Isoform 1 of Connective tissue growth factor, Profilin-1, Isoform 1 of Extracellular matrix protein 1, Histone H2B type 2-E, Kinesin-like protein KIF26A, Zinc finger protein 516, and Isoform 1 of A-kinase anchor protein 9.

Abstract: Disclosed are a composition for diagnosis of lung cancer including an antibody specific to GPI specific phospholipase D1 (GPLD1) protein, which is an effective biomarker for early diagnosis of lung cancer, and a composition for diagnosis of lung cancer including a primer or probe specific to a nucleic acid encoding the GPLD1 protein. The lung cancer diagnostic marker may be effectively used in early diagnosis of lung cancer and also, is very useful for evaluating progression of a disease and prognosis before and after treatment of the same.

Abstract: Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including Quescin-sulfhydryl oxidase 1, Fibrillin-1, Isoform A of Lamin-A/C, Latent-transforming growth factor beta-binding protein 2, Galectin-1, highly similar to Dickkopf-related protein 3, Isoform Al—B of Heterogeneous nuclear ribonucleoprotein Al, 14-3-3 protein epsilon, Stanniocalcin-2, Cystatin-C, Isoform 1 of Connective tissue growth factor, Profilin-1, Isoform 1 of Extracellular matrix protein 1, Histone H2B type 2-E, Kinesin-like protein KIF26A, Zinc finger protein 516, and Isoform 1 of A-kinase anchor protein 9.